Healthcare
36/100
36/100Is TRLV-Trulieve Cannabis a buy?
Saturday 20 June 2026
Why now: It is seeing unusually strong recent volume versus its prior baseline, which signals the market is paying attention again. But the price is still well below a clear resistance level, so this looks more like a volatile rebound than a clean long-term entry point today.
Upside: If it can reclaim and hold above $13.28 with improving fundamentals, upside could be meaningful because the stock is still well below its 52-week high. Without that, the more realistic upside is limited and can reverse quickly.
Risks: This is still a policy-sensitive business, and any delay or rollback in tax or scheduling benefits can hit profits fast. The chart does not show a confirmed breakout, so buyers risk getting chopped up in a range.
Sign up or log in for access
Unlock the full scorecard, detailed analysis, and research notes. Free, no credit card needed.
Scorecard
Read:Strong metricsSolid metricsSelectiveCautionUnfavourableN/A
| Scorecard | 36/100 | |
|---|---|---|
| Company Detail | TRLV, Trulieve Cannabis Corp. | |
| Price as at 18 June 2026 | $10.10 | |
| Market cap | $1.9B | |
| Quality and Fundamental Score (100) | ||
| Breakout / Early-Momentum /20 | 6/20 | |
| Rev/EPS Momentum /20 | 7/20 | |
| Business Quality /15 | 6/15 | |
| Balance Sheet /15 | 5/15 | |
| Valuation /10 | 5/10 | |
| Industry Relative Strength /10 | 0/10 | |
| Macro / Sector Tailwind /10 | 7/10 | |
| Growth | ||
| Cash runway | Cash generative | |
| Revenue YoY | -0.4% | |
| EPS YoY | +25.6% | |
| FCF YoY | +71.5% | |
| Gross margin | 60.2% | |
| Valuation & Trend | ||
| Trailing P/E | — | |
| Forward P/E | 42.1x | |
| RSI (14d) | 53 | |
| vs 50d SMA | +14.9% | |
| Support cushion | −27.3% | |
| Sentiment | ||
| Wall Street verdict | Mixed | |
| News tone | Mixed | |
| Dividend | — | |
How are these colored?
| Metric | Strong metrics | Solid metrics | Selective | Caution | Unfavourable |
|---|---|---|---|---|---|
| Overall score | ≥ 80 | 70-79 | 60-69 | 50-59 | < 50 |
| Business quality /15 | ≥ 12 | 10-11 | 8-9 | 6-7 | < 6 |
| Balance sheet /15 | ≥ 12 | 10-11 | 8-9 | 6-7 | < 6 |
| Market cap | ≥ $20B | $5B-$20B | $2B-$5B | $1B-$2B | < $1B |
| Cash runway | ≥ 3 yr or cash generative | 1.5-3 yr | 0.75-1.5 yr | 0.25-0.75 yr | < 0.25 yr |
| Revenue YoY | ≥ 15% | 5-15% | 0-5% | -5-0% | < -5% |
| EPS YoY | ≥ 20% | 5-20% | 0-5% | -5-0% | < -5% |
| FCF YoY | ≥ 10% | 1-10% | 0-1% | -5-0% | < -5% |
| Gross margin | ≥ 60% | 40-60% | 25-40% | 10-25% | < 10% |
| Trailing P/E | < 15 | 15-25 | 25-35 | 35-40 | > 40 or neg |
| Forward P/E | < 15 | 15-25 | 25-35 | 35-40 | > 40 or neg |
| RSI (14d) | 50-70 | 45-50 or 70-75 | 40-45 or 75-78 | 30-40 or 78-80 | < 30 or > 80 |
| vs 50d SMA | +2% to +15% | 0-2% or 15-25% | -2-0% or 25-35% | -3, 2% or 35-40% | < -3% or > 40% |
| Support cushion | 2-10% above | 0-2% | 10-15% | 15-20% | price below support |
| Wall Street verdict | Aligned | — | Mixed | — | Disagrees |
| News tone | Positive | — | Neutral / Mixed | — | Negative |
| Dividend | Yield ≥ 2% & growing | Growing | Flat payer ≥ 1% | Low / flat | Cutting |
Detailed Analysis, Saturday 20 June 2026
What they do
Trulieve Cannabis Corp. is a vertically integrated cannabis company that grows, manufactures, and sells cannabis products through its own retail stores in multiple U.S. states. It makes money by selling branded and in-house products directly to consumers, with a large concentration of operations in Florida.
Leadership
Kim RiversCEO
Kim Rivers has been Chief Executive Officer since September 2018.
Jan ReeseCFO
Jan Reese joined Trulieve as Chief Financial Officer in 2025.
Summary thesis
- Trulieve is a scaled operator with evidence of strong gross margin and meaningful cash generation, and the macro policy backdrop appears less hostile than in prior years.
- However, the stock’s live technical setup does not support a responsible long-term entry today, and the industry remains structurally risky and sentiment-driven.
- This is a “watch closely” name, not a “buy and hold confidently” name at the current price and chart position.
Wall Street alignment
Wall Street: Mixed signals (2 pos / 1 neg)
Analyst consensus
Strong Buy (1.14, 1 analysts) · +108% upside
Institutional ownership
11% institutions, insiders 4.2%
Smart money tape
+5 net (acc 7 / dist 2, last 26d)
Recent news
News Mixed · last 7d
Show 1 headline from the last 7d
2026-06-17Filing·
Director Wilson Davis files notice of proposed sale of shares · SEC
A director filed a notice of proposed sale covering multiple restricted stock unit share lots. This is a potential supply overhang signal, but it is not proof of executed sales.
Dividends
Pays no regular dividend.
Technicals
Price
$10.10
RSI (14d)
53.0
50d SMA
$8.79
200d SMA
$7.54
vs 50d SMA
+14.9%
vs 200d SMA
+33.9%
Support (swing low)
$7.35 −27.3%
40-day high (R)
$13.28 +31.5%
Next swing high (swing high)
$11.83 +17.1%
Close as of 2026-06-18.
Score breakdown
Scores 36 out of 100, a mixed overall grade. Sector fit and valuation were fair but not standout drivers. Business quality and earnings trend weighed on the total. Score capped because the live chart is not in a valid pre-breakout setup (no resistance break and no fresh 50-day reclaim), and the business remains highly exposed to regulatory and tax-rule uncertainty even after recent policy improvements.
Component scores are on the scorecard above.
Momentum evidence
- The stock has strong short-term returns over the last 20 and 90 trading days and very large volume expansion relative to its prior baseline, which usually signals fresh interest.
- At the same time, it is not holding above its key resistance level and the scan state is not a confirmed breakout, so the move looks unfinished and can fade if attention cools.
Fundamental evidence
- Trulieve reported full-year 2025 revenue around $1.2 billion and adjusted earnings power that looks strong on an operating basis, but it still posted a net loss for 2025.
- In Q1 2026, reported results showed about $287 million of revenue, high gross margin, adjusted earnings strength, and positive free cash flow, but a meaningful part of the profit improvement across the industry can be influenced by changes in tax treatment rather than only underlying demand.
- This is not a clean, stable earnings story yet, and investors should treat any single-quarter profit as “needs proof” until it repeats across multiple quarters.
Cash runway: Cash generative (latest annual free cash flow is positive).
Valuation view
At roughly a $2 billion market value, the stock is not priced like a distressed microcap anymore, but it is also not priced like a proven, low-risk consumer staples company. Valuation can look cheap on operating cash flow in good quarters, yet it can quickly look expensive if policy benefits disappoint or if state-level pricing pressure returns. This is a sector where multiples are unreliable because the rules can change the economics.
Macro tailwind
The key tailwind is the improving federal policy backdrop for certain medical cannabis activities, which can reduce tax friction and improve reported profitability and cash generation.
What to watch
Upcoming (1-6 months)
- Any material updates over the next 1 to 6 months on federal scheduling and tax interpretation for state-licensed medical operators, and whether Trulieve’s financial statements show sustained benefit.
Ongoing
- Quarterly free cash flow consistency and balance sheet discipline, plus whether revenue stabilizes or grows without relying on price cuts.
Long-term case
Over a multi-year horizon, the long-term bull case depends on (1) durable tax relief that meaningfully raises after-tax cash flow, (2) rational competition and pricing in core markets such as Florida, and (3) the company using improved cash generation to reduce leverage and avoid shareholder dilution. If these conditions hold, a scaled, vertically integrated operator can become a steadier cash-flow business over time. If they do not, the stock remains a policy-trading vehicle rather than a dependable long-term compounder.
Risks & invalidation
Risks
- Policy and tax interpretation risk remains high, and the industry can still face price compression and limited traditional banking access, which can quickly damage cash flow.
Breaks the thesis
- From a chart standpoint, failure to regain and hold above the $13.28 resistance area keeps the stock out of a proper long-term breakout setup and raises the odds the recent move was only a short-lived rebound.
Bottom line
MANUAL RESEARCH ONLY, the editor chose this ticker for a one-off evaluation, not as a pipeline winner. Trulieve is a real business with scale and improving cash flow signals, but it is still too policy-dependent and the chart is not in a clean long-term buy setup today. Do not buy this stock as a long-term holding at the current price; keep it on a watchlist and only reassess if profitability and cash flow stay strong for multiple quarters and the stock clears key resistance.